Plasma Lipidomic Phenotype Associated with Pathogenic LDLR Variants in Familial Hypercholesterolemia
5 affiliations
- 1Department of Medical Biology, National Institute of Cardiology, State Research Institute, 04-628 Warsaw, Poland
- 2Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, National Institute of Cardiology, State Research Institute, 04-628 Warsaw, Poland
- 3Clinical Research Support Centre, National Institute of Cardiology—State Research Institute, 04-628 Warsaw, Poland
- 4Heart Failure and Transplantology Clinic, National Institute of Cardiology—State Research Institute, 04-628 Warsaw, Poland
- 5Department of Medical Genetics, Medical University of Warsaw, 02-106 Warsaw, Poland
Abstract
Familial hypercholesterolemia (FH) is caused by an impaired ability to clear circulating low-density lipoprotein (LDL-C) particles due to a defective low-density lipoprotein receptor (LDLR). FH significantly increases cardiovascular risk (CVR). Although conventional lipid parameters are essential for diagnosing FH, they do not fully capture the metabolic impact of inherited LDLR dysfunction. This study aimed to characterize the plasma lipidomic phenotype associated with pathogenic LDLR variants in individuals with suspected FH. Forty-four participants underwent genetic testing for LDLR, apolipoprotein B-100 (APOB), and protein convertase subtilisin/kexin type 9 (PCSK9). After excluding three carriers of the APOB p.Arg3527Gln variant, the comparative lipidomic analysis included 41 participants. The study included 17 carriers of pathogenic LDLR variants and 24 participants without a detected pathogenic variant in the tested panel. We performed plasma lipidomic profiling using flow-injection analysis coupled with high-resolution tandem mass spectrometry (FIA-MS/MSALL) without chromatographic separation. Lipid annotation and data processing were performed using LipidView software, and lipidomic measurements were expressed as relative signal abundances derived from mass spectrometry (MS) peak intensities. Statistical analyses included Mann–Whitney U tests with false discovery rate (FDR) correction across the analyzed lipid features. Exploratory multivariable logistic regression and receiver operating characteristic (ROC) analyses were also performed. There were no differences in conventional lipid parameters between genetically confirmed LDLR variant carriers and participants without a detected pathogenic variant in the tested panel. At the nominal level (unadjusted p < 0.05), lipidomic profiling revealed differences in glycerophospholipid (GP) related analytical features between groups. However, no individual lipid feature remained statistically significant after full-family FDR correction. Among (GPs), 69 feature records (16.3%) showed nominal between-group differences, predominantly lower abundance in LDLR variant carriers. The most consistent nominal alterations were observed in features annotated as phosphatidylinositol triphosphates (PIP3) and N-acyl phosphatidylethanolamines (NAPE). Among the analyzed fatty acyls (FAs), 72.7% showed nominally lower relative abundance in LDLR variant carriers. We used exploratory multivariable models to identify GP and FA-related features associated with the detected pathogenic LDLR variant status. The models showed within-cohort discrimination. However, these models were developed and evaluated in the same small cohort after data-driven variable selection. They were not externally validated. Therefore, the findings should be interpreted as hypothesis-generating and do not establish diagnostic performance, clinical utility, or functional pathway impairment. Further validation in larger cohorts using targeted lipidomics with chromatographic separation is necessary.
Related
- A case of renal hypouricemia type 1 associated with compound heterozygous URAT1/SLC22A12 variants A209V and F379L: clinical evidence for their pathogenic significance
- Diagnostic Yield and Clinical Phenotype in a Lithuanian Familial Hypercholesterolemia Cohort with Heterogeneous Sequencing Platforms
- The population frequency of predicted pathogenic variants in the genes associated with Autosomal Dominant Polycystic Liver Disease (ADPLD) and kidney cysts
- Prevalence and Impact of a Pathogenic CYP27A1 Variant on the Phenotypes Among Patients with Monogenic Heterozygous Familial Hypercholesterolemia
- Little Evidence of Atherosclerosis in a Middle-aged Japanese Woman with Familial Hypercholesterolemia Carrying PCSK9 (p.Glu32Lys) and ABCG8 (p.Ile419Asn) Variants despite Elevated Lipoprotein (a) Levels
BibTeX
@article{was2026plasma,
title = {{Plasma Lipidomic Phenotype Associated with Pathogenic LDLR Variants in Familial Hypercholesterolemia}},
author = {Joanna Waś and Aleksander Prejbisz and Magdalena Niedolistek and Ilona Kowalik and Ilona Minota and Joanna Ponińska and Anna Drohomirecka and Dorota Sokołowska and Rafał Płoski and Piotr Dobrowolski},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209011},
url = {https://www.mdpi.com/1422-0067/27/20/9011},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Plasma Lipidomic Phenotype Associated with Pathogenic LDLR Variants in Familial Hypercholesterolemia
AU - Joanna Waś
AU - Aleksander Prejbisz
AU - Magdalena Niedolistek
AU - Ilona Kowalik
AU - Ilona Minota
AU - Joanna Ponińska
AU - Anna Drohomirecka
AU - Dorota Sokołowska
AU - Rafał Płoski
AU - Piotr Dobrowolski
PY - 2026
DA - 2026/10/01
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209011
UR - https://www.mdpi.com/1422-0067/27/20/9011
AB - Familial hypercholesterolemia (FH) is caused by an impaired ability to clear circulating low-density lipoprotein (LDL-C) particles due to a defective low-density lipoprotein receptor (LDLR). FH significantly increases cardiovascular risk (CVR). Although conventional lipid parameters are essential for diagnosing FH, they do not fully capture the metabolic impact of inherited LDLR dysfunction. This study aimed to characterize the plasma lipidomic phenotype associated with pathogenic LDLR variants in individuals with suspected FH. Forty-four participants underwent genetic testing for LDLR, apolipoprotein B-100 (APOB), and protein convertase subtilisin/kexin type 9 (PCSK9). After excluding three carriers of the APOB p.Arg3527Gln variant, the comparative lipidomic analysis included 41 participants. The study included 17 carriers of pathogenic LDLR variants and 24 participants without a detected pathogenic variant in the tested panel. We performed plasma lipidomic profiling using flow-injection analysis coupled with high-resolution tandem mass spectrometry (FIA-MS/MSALL) without chromatographic separation. Lipid annotation and data processing were performed using LipidView software, and lipidomic measurements were expressed as relative signal abundances derived from mass spectrometry (MS) peak intensities. Statistical analyses included Mann–Whitney U tests with false discovery rate (FDR) correction across the analyzed lipid features. Exploratory multivariable logistic regression and receiver operating characteristic (ROC) analyses were also performed. There were no differences in conventional lipid parameters between genetically confirmed LDLR variant carriers and participants without a detected pathogenic variant in the tested panel. At the nominal level (unadjusted p < 0.05), lipidomic profiling revealed differences in glycerophospholipid (GP) related analytical features between groups. However, no individual lipid feature remained statistically significant after full-family FDR correction. Among (GPs), 69 feature records (16.3%) showed nominal between-group differences, predominantly lower abundance in LDLR variant carriers. The most consistent nominal alterations were observed in features annotated as phosphatidylinositol triphosphates (PIP3) and N-acyl phosphatidylethanolamines (NAPE). Among the analyzed fatty acyls (FAs), 72.7% showed nominally lower relative abundance in LDLR variant carriers. We used exploratory multivariable models to identify GP and FA-related features associated with the detected pathogenic LDLR variant status. The models showed within-cohort discrimination. However, these models were developed and evaluated in the same small cohort after data-driven variable selection. They were not externally validated. Therefore, the findings should be interpreted as hypothesis-generating and do not establish diagnostic performance, clinical utility, or functional pathway impairment. Further validation in larger cohorts using targeted lipidomics with chromatographic separation is necessary.
SN - 1422-0067
ER -